Get the Stockscreener App
0.0002
60.00%
-0.0003
Syros Pharmaceuticals Inc stock is traded at $0.0002, with a volume of 53,206.
It is down -60.00% in the last 24 hours and down -60.00% over the past month.
See More
Previous Close:
$0.0005
Open:
$0.0002
24h Volume:
53,206
Relative Volume:
6.28
Market Cap:
$N/A
Revenue:
$9.94M
Net Income/Loss:
$-97.82M
P/E Ratio:
-0.000065
EPS:
-3.07
Net Cash Flow:
$-100.02M
1W Performance:
-60.00%
1M Performance:
-60.00%
6M Performance:
-88.24%
1Y Performance:
-99.50%
1-Day Range:
$0.0002
$0.0008
1-Week Range:
$0.0002
$0.0008
52-Week Range:
$0.0002
$0.0282
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Name
Syros Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare SYRS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.0002 | 0 | 9.94M | -97.82M | -100.02M | -3.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-19 | Resumed | JMP Securities | Mkt Outperform |
| Feb-14-19 | Resumed | Oppenheimer | Outperform |
| Nov-05-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-13-18 | Reiterated | Wedbush | Outperform |
| Oct-31-17 | Resumed | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | ROTH Capital | Neutral |
| Aug-10-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
View All
Syros Pharmaceuticals Inc Stock (SYRS) Latest News
MSN - MSN
MSN Money - MSN
Myelodysplastic Syndrome Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Globe and Mail
Reviewing Vectura Group (OTCMKTS:VEGPF) and Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Head-To-Head Review: Aerovate Therapeutics (NASDAQ:AVTE) vs. Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Syros to delist from Nasdaq, deregister from SEC - MSN
SYRS (Syros Pharmaceuticals) Price-to-Tangible-Book : (As of Oct. 22, 2025) - GuruFocus
CapEx per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView
Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN
Net current asset value per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView
JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN
AKPKD Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeut - The Globe and Mail
Myelodysplastic Syndrome Pipeline Analysis, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, - Barchart.com
Syros Pharmaceuticals, Inc. (SYRS) stock price, news, quote and history - Yahoo Finance Singapore
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital - GlobeNewswire
Syros Pharmaceuticals (SYRS) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire
SYRS Stock Price, News & Analysis - stocktitan.net
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus
Syros Pharma pulls out of deal with RaQualia - The Pharma Letter
SYRS Stock Price and Chart — OTC:SYRS - TradingView
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), State Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga
Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations - Stock Titan
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN
Syros Pharmaceuticals stock plunges to 52-week low of $0.16 - Investing.com
Odyssey hires Jason Haas as CFO - BioCentury
Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com
BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President - Business Wire
Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com Australia
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - Nasdaq
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Yahoo Finance
No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld MedTech
Syros stock dives 92% on failed Phase 3 study, possible loan default (NASDAQ:SYRS) - Seeking Alpha
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - Business Wire
CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 | DelveInsight - The Malaysian Reserve
Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock - simplywall.st
Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) - Yahoo Finance
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gew - GuruFocus
Syros Pharmaceuticals, Inc. (SYRS) Investigation: - GlobeNewswire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings - Business Wire
How to contact the Daily Bulletin - FinancialContent
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - PR Newswire
Syros Pharmaceuticals Inc Stock (SYRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.90%
2.73%
Cap:
|
Volume (24h):